Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| FF EAI Robotics Ecosystem Inc.QLGN · Entity 7776 | Director | July 11, 2022 | August 04, 2022 |
| LIFECORE BIOMEDICAL, INC. \DE\LFCR · Entity 6447 | Director | June 04, 2026 | June 05, 2026 |
| LIGAND PHARMACEUTICALS INCLGND · Entity 3825 | President & COO | September 20, 2024 | September 24, 2024 |
| PALVELLA THERAPEUTICS, INC.PVLA · Entity 4452 | CFO, Treasurer | June 12, 2026 | June 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
FF EAI Robotics Ecosystem Inc.
Report date July 11, 2022 · Filed August 04, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.51 · Expires 2032-07-11 | Direct | 40,000 |
Reported balance
After 2022-07-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-07-11 · Grant · Acquired 40,000 · Balance 40,000 F1: Shares underlying the stock option vest over three years in equal annual installments from the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares underlying the stock option vest over three years in equal annual installments from the date of grant.
LIFECORE BIOMEDICAL, INC. \DE\
Report date June 04, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 69,967 |
Reported balance
After 2026-06-04 transaction · row 1
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 25,907 · Balance 69,967 F1: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis. F2: Vests on earlier of June 4, 2027 or the date of the annual meeting of stockholders of the Company first held in calendar year 2027 (provided such date is no less than 50 weeks from June 4, 2026). |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.
F2: Vests on earlier of June 4, 2027 or the date of the annual meeting of stockholders of the Company first held in calendar year 2027 (provided such date is no less than 50 weeks from June 4, 2026).
LIGAND PHARMACEUTICALS INC
Report date September 20, 2024 · Filed September 24, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 50,777 |
Ending reported balance
After 2024-09-23 transaction · row 7
7 source rows · reconciled sequenceRow 1 · 2024-09-20 · Exercise / conversion · Acquired 4,982 · Balance 57,052 Row 2 · 2024-09-20 · Sale · Disposed 6,275 · Balance 50,777 F1: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $104.0000 to $104.4300. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 3 · 2024-09-23 · Exercise / conversion · Acquired 395 · Balance 51,172 Row 4 · 2024-09-23 · Exercise / conversion · Acquired 9,377 · Balance 60,549 Row 5 · 2024-09-23 · Sale · Disposed 2,481 · Balance 58,068 F2: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $100.0000 to $100.2750. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 6 · 2024-09-23 · Sale · Disposed 7,090 · Balance 50,978 F3: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $101.0450 to $102.0400. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 7 · 2024-09-23 · Sale · Disposed 201 · Balance 50,777 F4: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $102.0450 to $102.0950. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $49.99 · Expires 2026-02-11 | Direct | 395 |
Reported balance
After 2024-09-20 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2024-09-20 · Exercise / conversion · Disposed 4,982 · Balance 395 F5: This Option was previously reported as a Grant of 18,464 shares on February 11, 2016, which vested in full on February 11, 2020, at an exercise price of $85.79 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $49.99 · Expires 2026-02-11 | Direct | 0 |
Reported balance
After 2024-09-23 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2024-09-23 · Exercise / conversion · Disposed 395 · Balance 0 F5: This Option was previously reported as a Grant of 18,464 shares on February 11, 2016, which vested in full on February 11, 2020, at an exercise price of $85.79 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $52.84 · Expires 2032-05-05 | Direct | 42,436 |
Reported balance
After 2024-09-23 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2024-09-23 · Exercise / conversion · Disposed 9,377 · Balance 42,436 F6: This Option was previously reported as a Grant of 30,189 shares on May 5, 2022, at an exercise price of $90.68 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer and shall be fully vested on February 5, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $104.0000 to $104.4300. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $100.0000 to $100.2750. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $101.0450 to $102.0400. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $102.0450 to $102.0950. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5: This Option was previously reported as a Grant of 18,464 shares on February 11, 2016, which vested in full on February 11, 2020, at an exercise price of $85.79 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer.
F6: This Option was previously reported as a Grant of 30,189 shares on May 5, 2022, at an exercise price of $90.68 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer and shall be fully vested on February 5, 2026.
PALVELLA THERAPEUTICS, INC.
Report date June 12, 2026 · Filed June 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,000 |
Reported balance
After 2026-06-12 transaction · row 1
1 source rowRow 1 · 2026-06-12 · Exercise / conversion · Acquired 1,000 · Balance 1,000 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.60 · Expires 2034-12-13 | Direct | 166,100 |
Reported balance
After 2026-06-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-12 · Exercise / conversion · Disposed 1,000 · Balance 166,100 F1: 25% of the stock options will vest on October 16, 2025, and the remaining 75% will vest in equal monthly tranches over the following 36 months. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the stock options will vest on October 16, 2025, and the remaining 75% will vest in equal monthly tranches over the following 36 months.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 12, 2026 Filed Jun 16, 2026 20:05 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,000 | $0.00 Strike: $13.60 | $0.00 |
DisclosureSEC source: 0001104659-26-074574 · tm2618034-1_4seq1.xml · derivative · entry 2 Korenberg Matthew E · CIK 0001649903 · CFO, Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 166,100 Underlying: Common Stock · 1,000 shares Expires 2034-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the stock options will vest on October 16, 2025, and the remaining 75% will vest in equal monthly tranches over the following 36 months. Read SEC document |
| June 12, 2026 Filed Jun 16, 2026 20:05 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | Exercise / conversionCommon Stock | 1,000 | $13.60 | $13,600.00 |
DisclosureSEC source: 0001104659-26-074574 · tm2618034-1_4seq1.xml · nonDerivative · entry 1 Korenberg Matthew E · CIK 0001649903 · CFO, Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 04, 2026 Filed Jun 5, 2026 20:46 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LFCR · Entity 6447 | GrantCommon Stock | 25,907 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001649903-26-000002 · wk-form4_1780692359.xml · nonDerivative · entry 1 Korenberg Matthew E · CIK 0001649903 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,967 F1 · price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis. F2 · price: Vests on earlier of June 4, 2027 or the date of the annual meeting of stockholders of the Company first held in calendar year 2027 (provided such date is no less than 50 weeks from June 4, 2026). Read SEC document |
| February 05, 2026 Filed Feb 9, 2026 21:06 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | GrantStock Option (Right to Buy) · Derivative | 44,123 | $0.00 Strike: $76.43 | $0.00 |
DisclosureSEC source: 0001104659-26-012064 · tm265512-2_4seq1.xml · derivative · entry 1 Korenberg Matthew E · CIK 0001649903 · CFO, Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,123 Underlying: Common Stock · 44,123 shares Expires 2036-02-05 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in equal monthly installments over 48 months commencing from February 5, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| July 15, 2025 Filed Jul 17, 2025 20:41 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LFCR · Entity 6447 | GrantCommon Stock | 19,506 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001005286-25-000090 · wk-form4_1752784888.xml · nonDerivative · entry 1 Korenberg Matthew E · CIK 0001649903 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,060 F1 · price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis. F2 · price: Vests on the earlier of the one year anniversary of the date hereof or the date of the annual meeting of stockholders of the Company first held in calendar year 2026 (provided such date is no less than 50 weeks from the date hereof). Read SEC document |
| February 05, 2025 Filed Feb 10, 2025 22:21 UTC Amendment | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 123,559 | $0.00 Strike: $14.76 | $0.00 |
DisclosureSEC source: 0001583648-25-000017 · edgardoc.xml · derivative · entry 2 Korenberg Matthew E · CIK 0001649903 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,559 Underlying: Common Stock · 123,559 shares Expires 2035-02-05 F1 · derivative.exercise_date: The stock options will vest in equal monthly tranches over 48 months Read SEC document |
| February 05, 2025 Filed Feb 10, 2025 22:21 UTC Amendment | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | GrantIncentive Stock Option (right to buy) · Derivative | 5,373 | $0.00 Strike: $14.76 | $0.00 |
DisclosureSEC source: 0001583648-25-000017 · edgardoc.xml · derivative · entry 1 Korenberg Matthew E · CIK 0001649903 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,373 Underlying: Common Stock · 5,373 shares Expires 2035-02-05 F1 · derivative.exercise_date: The stock options will vest in equal monthly tranches over 48 months Read SEC document |
| December 13, 2024 Filed Dec 18, 2024 01:43 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | GrantStock Option (right to buy) · Derivative | 167,100 | $0.00 Strike: $13.60 | $0.00 |
DisclosureSEC source: 0001062993-24-020818 · form4.xml · derivative · entry 1 Korenberg Matthew E · CIK 0001649903 · CFO, Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 167,100 Underlying: Common Stock · 167,100 shares Expires 2034-12-13 F1 · derivative.exercise_date: 25% of the stock options will vest on October 16, 2025, and the remaining 75% will vest in equal monthly tranches over the following 36 months. Read SEC document |
| September 23, 2024 Filed Sep 24, 2024 23:41 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 9,377 | $0.00 Strike: $52.84 | $0.00 |
DisclosureSEC source: 0002001011-24-000087 · edgardoc.xml · derivative · entry 10 Korenberg Matthew E · CIK 0001649903 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,436 Underlying: Common Stock · 9,377 shares Expires 2032-05-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: This Option was previously reported as a Grant of 30,189 shares on May 5, 2022, at an exercise price of $90.68 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer and shall be fully vested on February 5, 2026. Read SEC document |
| September 23, 2024 Filed Sep 24, 2024 23:41 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 395 | $0.00 Strike: $49.99 | $0.00 |
DisclosureSEC source: 0002001011-24-000087 · edgardoc.xml · derivative · entry 9 Korenberg Matthew E · CIK 0001649903 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 395 shares Expires 2026-02-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This Option was previously reported as a Grant of 18,464 shares on February 11, 2016, which vested in full on February 11, 2020, at an exercise price of $85.79 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer. Read SEC document |
| September 23, 2024 Filed Sep 24, 2024 23:41 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 201 | $102.05 | $20,512.87 |
DisclosureSEC source: 0002001011-24-000087 · edgardoc.xml · nonDerivative · entry 7 Korenberg Matthew E · CIK 0001649903 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,777 F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $102.0450 to $102.0950. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 23, 2024 Filed Sep 24, 2024 23:41 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 7,090 | $101.61 | $720,379.45 |
DisclosureSEC source: 0002001011-24-000087 · edgardoc.xml · nonDerivative · entry 6 Korenberg Matthew E · CIK 0001649903 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,978 F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $101.0450 to $102.0400. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 23, 2024 Filed Sep 24, 2024 23:41 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 2,481 | $100.05 | $248,228.27 |
DisclosureSEC source: 0002001011-24-000087 · edgardoc.xml · nonDerivative · entry 5 Korenberg Matthew E · CIK 0001649903 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,068 F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $100.0000 to $100.2750. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 23, 2024 Filed Sep 24, 2024 23:41 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 9,377 | $52.84 | $495,480.68 |
DisclosureSEC source: 0002001011-24-000087 · edgardoc.xml · nonDerivative · entry 4 Korenberg Matthew E · CIK 0001649903 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,549 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 23, 2024 Filed Sep 24, 2024 23:41 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 395 | $49.99 | $19,746.05 |
DisclosureSEC source: 0002001011-24-000087 · edgardoc.xml · nonDerivative · entry 3 Korenberg Matthew E · CIK 0001649903 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,172 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 20, 2024 Filed Sep 24, 2024 23:41 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 4,982 | $0.00 Strike: $49.99 | $0.00 |
DisclosureSEC source: 0002001011-24-000087 · edgardoc.xml · derivative · entry 8 Korenberg Matthew E · CIK 0001649903 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 395 Underlying: Common Stock · 4,982 shares Expires 2026-02-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This Option was previously reported as a Grant of 18,464 shares on February 11, 2016, which vested in full on February 11, 2020, at an exercise price of $85.79 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer. Read SEC document |
| September 20, 2024 Filed Sep 24, 2024 23:41 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 6,275 | $104.10 | $653,238.17 |
DisclosureSEC source: 0002001011-24-000087 · edgardoc.xml · nonDerivative · entry 2 Korenberg Matthew E · CIK 0001649903 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,777 F1 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $104.0000 to $104.4300. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 20, 2024 Filed Sep 24, 2024 23:41 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 4,982 | $49.99 | $249,050.18 |
DisclosureSEC source: 0002001011-24-000087 · edgardoc.xml · nonDerivative · entry 1 Korenberg Matthew E · CIK 0001649903 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,052 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 16, 2024 Filed Sep 18, 2024 23:55 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 3,340 | $0.00 Strike: $60.94 | $0.00 |
DisclosureSEC source: 0002001011-24-000082 · edgardoc.xml · derivative · entry 12 Korenberg Matthew E · CIK 0001649903 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,500 Underlying: Common Stock · 3,340 shares Expires 2025-08-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: This Option was previously reported as a Grant of 25,000 shares on August 06, 2015, which vested in full on August 06, 2019, at an exercise price of $104.59 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer. F4 · derivative.exercise_date: This Option was previously reported as a Grant of 25,000 shares on August 06, 2015, which vested in full on August 06, 2019, at an exercise price of $104.59 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer. Read SEC document |
| September 16, 2024 Filed Sep 18, 2024 23:55 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 849 | $0.00 Strike: $58.49 | $0.00 |
DisclosureSEC source: 0002001011-24-000082 · edgardoc.xml · derivative · entry 11 Korenberg Matthew E · CIK 0001649903 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,452 Underlying: Common Stock · 849 shares Expires 2027-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: This Option was previously reported as a Grant of 15,225 shares on February 24, 2017, which vested in full on February 24, 2021, at an exercise price of $100.38 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer. F3 · derivative.exercise_date: This Option was previously reported as a Grant of 15,225 shares on February 24, 2017, which vested in full on February 24, 2021, at an exercise price of $100.38 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer. Read SEC document |
| September 16, 2024 Filed Sep 18, 2024 23:55 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 914 | $0.00 Strike: $55.75 | $0.00 |
DisclosureSEC source: 0002001011-24-000082 · edgardoc.xml · derivative · entry 10 Korenberg Matthew E · CIK 0001649903 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,949 Underlying: Common Stock · 914 shares Expires 2030-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: This Option was previously reported as a Grant of 30,750 shares on February 13, 2020, at an exercise price of $95.68 per share , but was adjusted pursuant to the OmniAb Inc. separation from the issuer, then vested in full on February 13, 2024. F2 · derivative.exercise_date: This Option was previously reported as a Grant of 30,750 shares on February 13, 2020, at an exercise price of $95.68 per share , but was adjusted pursuant to the OmniAb Inc. separation from the issuer, then vested in full on February 13, 2024. Read SEC document |
| September 16, 2024 Filed Sep 18, 2024 23:55 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 671 | $0.00 Strike: $49.99 | $0.00 |
DisclosureSEC source: 0002001011-24-000082 · edgardoc.xml · derivative · entry 9 Korenberg Matthew E · CIK 0001649903 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,377 Underlying: Common Stock · 671 shares Expires 2026-02-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: This Option was previously reported as a Grant of 18,464 shares on February 11, 2016, which vested in full on February 11, 2020, at an exercise price of $85.79 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer. F1 · derivative.exercise_date: This Option was previously reported as a Grant of 18,464 shares on February 11, 2016, which vested in full on February 11, 2020, at an exercise price of $85.79 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer. Read SEC document |
| September 16, 2024 Filed Sep 18, 2024 23:55 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 1,938 | $105.00 | $203,490.00 |
DisclosureSEC source: 0002001011-24-000082 · edgardoc.xml · nonDerivative · entry 8 Korenberg Matthew E · CIK 0001649903 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,070 Read SEC document |
| September 16, 2024 Filed Sep 18, 2024 23:55 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 3,340 | $60.94 | $203,539.60 |
DisclosureSEC source: 0002001011-24-000082 · edgardoc.xml · nonDerivative · entry 7 Korenberg Matthew E · CIK 0001649903 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,008 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 16, 2024 Filed Sep 18, 2024 23:55 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 319 | $105.00 | $33,495.00 |
DisclosureSEC source: 0002001011-24-000082 · edgardoc.xml · nonDerivative · entry 6 Korenberg Matthew E · CIK 0001649903 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,668 Read SEC document |
| September 16, 2024 Filed Sep 18, 2024 23:55 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 671 | $49.99 | $33,543.29 |
DisclosureSEC source: 0002001011-24-000082 · edgardoc.xml · nonDerivative · entry 5 Korenberg Matthew E · CIK 0001649903 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,987 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 16, 2024 Filed Sep 18, 2024 23:55 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 472 | $105.00 | $49,560.00 |
DisclosureSEC source: 0002001011-24-000082 · edgardoc.xml · nonDerivative · entry 4 Korenberg Matthew E · CIK 0001649903 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,316 Read SEC document |
| September 16, 2024 Filed Sep 18, 2024 23:55 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 849 | $58.49 | $49,658.01 |
DisclosureSEC source: 0002001011-24-000082 · edgardoc.xml · nonDerivative · entry 3 Korenberg Matthew E · CIK 0001649903 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,788 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 16, 2024 Filed Sep 18, 2024 23:55 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 485 | $105.00 | $50,925.00 |
DisclosureSEC source: 0002001011-24-000082 · edgardoc.xml · nonDerivative · entry 2 Korenberg Matthew E · CIK 0001649903 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,939 Read SEC document |
| September 16, 2024 Filed Sep 18, 2024 23:55 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 914 | $55.75 | $50,955.50 |
DisclosureSEC source: 0002001011-24-000082 · edgardoc.xml · nonDerivative · entry 1 Korenberg Matthew E · CIK 0001649903 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,424 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 26, 2024 Filed Aug 27, 2024 00:15 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 5,212 | $106.32 | $554,147.14 |
DisclosureSEC source: 0002001011-24-000078 · edgardoc.xml · nonDerivative · entry 5 Korenberg Matthew E · CIK 0001649903 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,510 F5 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $105.8100 to $106.6900. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 26, 2024 Filed Aug 27, 2024 00:15 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 6,177 | $105.02 | $648,683.83 |
DisclosureSEC source: 0002001011-24-000078 · edgardoc.xml · nonDerivative · entry 4 Korenberg Matthew E · CIK 0001649903 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,722 F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $104.7200 to $105.6700. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 23, 2024 Filed Aug 27, 2024 00:15 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 4,275 | $105.13 | $449,438.87 |
DisclosureSEC source: 0002001011-24-000078 · edgardoc.xml · nonDerivative · entry 3 Korenberg Matthew E · CIK 0001649903 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,899 F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $105.0000 to $105.4450. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 23, 2024 Filed Aug 27, 2024 00:15 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 2,037 | $104.09 | $212,040.50 |
DisclosureSEC source: 0002001011-24-000078 · edgardoc.xml · nonDerivative · entry 2 Korenberg Matthew E · CIK 0001649903 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,174 F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $104.0000 to $104.3800. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 22, 2024 Filed Aug 27, 2024 00:15 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 1,157 | $105.54 | $122,109.78 |
DisclosureSEC source: 0002001011-24-000078 · edgardoc.xml · nonDerivative · entry 1 Korenberg Matthew E · CIK 0001649903 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,211 F1 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $105.2500 to $105.6500. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 23:52 UTC | LIFECORE BIOMEDICAL, INC. \DE\ LFCR · Entity 6447 | GrantCommon Stock | 24,554 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-24-038088 · wk-form4_1724284348.xml · nonDerivative · entry 1 Korenberg Matthew E · CIK 0001649903 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,554 F1 · price: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis. F2 · price: Vests on earlier of July 8, 2025 or the date of the annual meeting of stockholders of the Company first held in calendar year 2025 (provided such date is no less than 50 weeks from July 8, 2024). Read SEC document |
| August 09, 2024 Filed Aug 13, 2024 21:21 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 18,245 | $98.50 | $1,797,132.50 |
DisclosureSEC source: 0002001011-24-000071 · edgardoc.xml · nonDerivative · entry 1 Korenberg Matthew E · CIK 0001649903 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,368 Read SEC document |
| June 28, 2024 Filed Jul 2, 2024 23:45 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | OtherCommon Stock | 350 | $60.71 | $21,247.45 |
DisclosureSEC source: 0002001011-24-000064 · edgardoc.xml · nonDerivative · entry 1 Korenberg Matthew E · CIK 0001649903 · President & Chief Operating 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,613 F1 · kind: These shares were acquired under the Ligand Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| May 14, 2024 Filed May 15, 2024 23:34 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 520 | $85.68 | $44,555.73 |
DisclosureSEC source: 0002001011-24-000052 · edgardoc.xml · nonDerivative · entry 3 Korenberg Matthew E · CIK 0001649903 · President & Chief Operating 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,263 F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $85.6250 to $85.7650. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 14, 2024 Filed May 15, 2024 23:34 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 13,638 | $85.08 | $1,160,356.50 |
DisclosureSEC source: 0002001011-24-000052 · edgardoc.xml · nonDerivative · entry 2 Korenberg Matthew E · CIK 0001649903 · President & Chief Operating 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,783 F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $84.5950 to $85.5500. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 13, 2024 Filed May 15, 2024 23:34 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 3,440 | $84.54 | $290,828.26 |
DisclosureSEC source: 0002001011-24-000052 · edgardoc.xml · nonDerivative · entry 1 Korenberg Matthew E · CIK 0001649903 · President & Chief Operating 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,421 F1 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $84.5000 to $84.8750. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 23:50 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantEmployee Stock Option (right to buy) · Derivative | 58,544 | $0.00 Strike: $89.20 | $0.00 |
DisclosureSEC source: 0002001011-24-000029 · edgardoc.xml · derivative · entry 2 Korenberg Matthew E · CIK 0001649903 · PRESIDENT & CHIEF OPERATING 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,544 Underlying: Common Stock · 58,544 shares Expires 2034-02-27 F2 · derivative.exercise_date: The Stock Option grant vests and is exercisable as to 12.5% of the underlying shares 6 months after the grant date, and in 42 substantially equal monthly installments thereafter. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 23:50 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 14,416 | $0.00 | $0.00 |
DisclosureSEC source: 0002001011-24-000029 · edgardoc.xml · nonDerivative · entry 1 Korenberg Matthew E · CIK 0001649903 · PRESIDENT & CHIEF OPERATING 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,861 F1 · shares: Represents Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest over three years, in three substantially equal annual installments on February 15, 2025; February 15, 2026; and February 15, 2027, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document |
| February 15, 2024 Filed Feb 17, 2024 01:10 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 4,778 | $74.65 | $356,677.70 |
DisclosureSEC source: 0002001011-24-000018 · edgardoc.xml · nonDerivative · entry 1 Korenberg Matthew E · CIK 0001649903 · PRESIDENT & CHIEF OPERATING 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,445 F1 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:07 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 2,917 | $72.31 | $210,928.27 |
DisclosureSEC source: 0002001011-24-000009 · edgardoc.xml · nonDerivative · entry 1 Korenberg Matthew E · CIK 0001649903 · PRESIDENT & CHIEF OPERATING 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,223 F1 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units. Read SEC document |
| December 05, 2023 Filed Dec 6, 2023 20:27 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 1,984 | $59.61 | $118,266.24 |
DisclosureSEC source: 0002001011-23-000003 · edgardoc.xml · nonDerivative · entry 1 Korenberg Matthew E · CIK 0001649903 · PRESIDENT & CHIEF OPERATING 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,140 F1 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units. Read SEC document |
| June 30, 2023 Filed Jul 10, 2023 22:42 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | OtherCommon Stock | 376 | $56.78 | $21,349.28 |
DisclosureSEC source: 0000886163-23-000045 · edgardoc.xml · nonDerivative · entry 1 Korenberg Matthew E · CIK 0001649903 · PRESIDENT & CHIEF OPERATING 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,124 F1 · kind: Shares acquired under Ligand's employee stock purchase plan. Voluntary reporting exemption under Rule 16b-3(c). Read SEC document |
| February 23, 2023 Filed Feb 28, 2023 01:52 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantEmployee Stock Option (right to buy) · Derivative | 24,628 | $0.00 Strike: $75.09 | $0.00 |
DisclosureSEC source: 0000899243-23-006297 · doc4.xml · derivative · entry 2 Korenberg Matthew E · CIK 0001649903 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,628 Underlying: Common Stock · 24,628 shares Expires 2033-02-23 F2 · derivative.exercise_date: Grant to reporting person of stock options that will vest and become exercisable over a 4-year period measured from February 23, 2023, with 12-1/2% of the shares subject to the stock options vesting on the date that is six months after February 23, 2023 and the remaining stock options vesting in 42 equal monthly installments thereafter. Read SEC document |
| February 23, 2023 Filed Feb 28, 2023 01:52 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 9,069 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-006297 · doc4.xml · nonDerivative · entry 1 Korenberg Matthew E · CIK 0001649903 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,748 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest over three years, in three equal annual installments on February 15, 2024; February 15, 2025; and February 15, 2026, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document |
| February 15, 2023 Filed Feb 18, 2023 00:23 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 2,890 | $72.98 | $210,912.20 |
DisclosureSEC source: 0000899243-23-005552 · doc4.xml · nonDerivative · entry 1 Korenberg Matthew E · CIK 0001649903 · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,679 F1 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.